NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $15.88 +0.50 (+3.25%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$15.59 -0.29 (-1.81%) As of 05/22/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rallybio Stock (NASDAQ:RLYB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rallybio alerts:Sign Up Key Stats Today's Range$15.46▼$16.0050-Day Range$8.04▼$15.8852-Week Range$2.16▼$16.00Volume64,488 shsAverage Volume646,322 shsMarket Capitalization$84.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Rallybio Therapeutics, Inc. (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options. Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency. Additional pipeline candidates target lysosomal storage disorders and severe skin fragility syndromes, underscoring the company’s commitment to a precision‐medicine approach. Each program has been selected based on compelling preclinical or early clinical data that suggest a clear path to regulatory milestones and commercialization. Founded in 2018 and headquartered in New York City, Rallybio completed its initial public offering via a business combination in 2021. The company leverages strategic partnerships, external research collaborations and internal manufacturing capabilities to accelerate development timelines and maintain rigorous quality standards. While Rallybio’s primary operations are based in the United States, its clinical trial network spans North America, Europe and Asia Pacific, reflecting its objective to serve rare disease communities on a global scale. Rallybio is led by a management team with extensive experience in rare disease research, drug development and regulatory strategy. The company aims to build on its scientific foundation by expanding its pipeline, advancing key assets toward commercialization and fostering collaborations that enhance access to therapies for underserved patient populations worldwide.AI Generated. May Contain Errors. Read More Rallybio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreRLYB MarketRank™: Rallybio scored higher than 20% of companies evaluated by MarketBeat, and ranked 792nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRallybio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRallybio has only been the subject of 1 research reports in the past 90 days.Read more about Rallybio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rallybio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted33.15% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 28.85, which indicates bearish sentiment.Change versus previous monthShort interest in Rallybio has recently increased by 11.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. News and Social Media4.7 / 5News Sentiment1.49 News SentimentRallybio has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Rallybio this week, compared to 1 article on an average week.Search Interest9 people have searched for RLYB on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows2 people have added Rallybio to their MarketBeat watchlist in the last 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $4,229,715.00 in company stock, which represents 5.0256% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,229,715.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.30% of the stock of Rallybio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLYB Stock News HeadlinesRallybio CorporationMay 22 at 6:06 PM | edition.cnn.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 6,009 SharesMay 21 at 8:07 AM | insidertrades.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.May 24 at 1:00 AM | Porter & Company (Ad)Adar1 Capital Management, Llc Purchases 79,259 Shares of Rallybio (NASDAQ:RLYB) StockMay 17, 2026 | americanbankingnews.comAdar1 Capital Management buys $1.11m of Rallybio (RLYB) stockMay 16, 2026 | investing.comInsider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Purchases 79,259 Shares of StockMay 16, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 SharesMay 14, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 35,101 SharesMay 7, 2026 | insidertrades.comSee More Headlines RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $5.4888 at the beginning of the year. Since then, RLYB stock has increased by 189.3% and is now trading at $15.88. How were Rallybio's earnings last quarter? Rallybio Corporation (NASDAQ:RLYB) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.26. The business earned $0.21 million during the quarter, compared to analyst estimates of $0.21 million. Rallybio had a negative trailing twelve-month return on equity of 55.79% and a negative net margin of 911.07%. When did Rallybio's stock split? Rallybio's stock reverse split before market open on Friday, February 6th 2026.The 1-8 reverse split was announced on Tuesday, February 3rd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Rallybio IPO? Rallybio (RLYB) raised $87 million in an IPO on Wednesday, July 28th 2021. The company issued 6,200,000 shares at $13.00-$15.00 per share. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rallybio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG). Company Calendar Last Earnings5/13/2026Today5/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RLYB's financial health is in the Green zone, according to TradeSmith. RLYB has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLYB CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.98 million Net Margins-911.07% Pretax Margin-877.62% Return on Equity-55.79% Return on Assets-51.48% Debt Debt-to-Equity RatioN/A Current Ratio12.92 Quick Ratio12.92 Sales & Book Value Annual Sales$860 thousand Price / Sales97.87 Cash FlowN/A Price / Cash FlowN/A Book Value$9.49 per share Price / Book1.67Miscellaneous Outstanding Shares5,300,000Free Float4,752,000Market Cap$84.16 million OptionableNot Optionable Beta-1.10 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:RLYB) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
